Pan Malayan plans to eventually market Gynazole-1 in a total of six countries in the Asian region.
Marc Hermelin, vice chairman and CEO of KV stated, “The Pan Malayan approval marks the first for Gynazole-1 in the Asian region, and Singapore is an ideal market in which to get started given its designation as a reference country within the region.”
Pan Malayan expects to begin introduction of the product, which will be marketed in Singapore as Gynafort, during the second half of the company’s current fiscal year.